The stock of Wave Life Sciences Ltd. (WVE) has gone up by 13.17% for the week, with a -9.28% drop in the past month and a 31.25% rise in the past quarter. The volatility ratio for the week is 6.77%, and the volatility levels for the past 30 days are 6.70% for WVE. The simple moving average for the last 20 days is 6.25% for WVE stock, with a simple moving average of 11.92% for the last 200 days.
Is It Worth Investing in Wave Life Sciences Ltd. (NASDAQ: WVE) Right Now?
Moreover, the 36-month beta value for WVE is -1.00. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for WVE is 96.38M and currently, short sellers hold a 3.27% of that float. On May 02, 2024, WVE’s average trading volume was 891.72K shares.
WVE) stock’s latest price update
The stock price of Wave Life Sciences Ltd. (NASDAQ: WVE) has surged by 15.01 when compared to previous closing price of 4.93, but the company has seen a 13.17% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-27 that CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April.
Analysts’ Opinion of WVE
Many brokerage firms have already submitted their reports for WVE stocks, with Leerink Partners repeating the rating for WVE by listing it as a “Outperform.” The predicted price for WVE in the upcoming period, according to Leerink Partners is $12 based on the research report published on December 19, 2023 of the previous year 2023.
Raymond James, on the other hand, stated in their research note that they expect to see WVE reach a price target of $7. The rating they have provided for WVE stocks is “Outperform” according to the report published on July 05th, 2023.
Jefferies gave a rating of “Hold” to WVE, setting the target price at $5 in the report published on May 24th of the previous year.
WVE Trading at 2.42% from the 50-Day Moving Average
After a stumble in the market that brought WVE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.08% of loss for the given period.
Volatility was left at 6.70%, however, over the last 30 days, the volatility rate increased by 6.77%, as shares sank -4.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.96% upper at present.
During the last 5 trading sessions, WVE rose by +13.17%, which changed the moving average for the period of 200-days by +36.63% in comparison to the 20-day moving average, which settled at $5.32. In addition, Wave Life Sciences Ltd. saw 12.28% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WVE starting from Moran Kyle, who sale 15,630 shares at the price of $6.17 back on Apr 03 ’24. After this action, Moran Kyle now owns 33,921 shares of Wave Life Sciences Ltd., valued at $96,421 using the latest closing price.
RA CAPITAL MANAGEMENT, L.P., the Director of Wave Life Sciences Ltd., purchase 1,000,000 shares at $5.00 during a trade that took place back on Dec 11 ’23, which means that RA CAPITAL MANAGEMENT, L.P. is holding 19,202,009 shares at $5,000,000 based on the most recent closing price.
Stock Fundamentals for WVE
Current profitability levels for the company are sitting at:
- -0.6 for the present operating margin
- 0.92 for the gross margin
The net margin for Wave Life Sciences Ltd. stands at -0.48. The total capital return value is set at -0.77. Equity return is now at value -1123.17, with -27.42 for asset returns.
Based on Wave Life Sciences Ltd. (WVE), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at -0.6. The debt to equity ratio resting at 0.68. The interest coverage ratio of the stock is 23.61.
Currently, EBITDA for the company is -58.79 million with net debt to EBITDA at 2.49. When we switch over and look at the enterprise to sales, we see a ratio of 4.63. The receivables turnover for the company is 5.37for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
To wrap up, the performance of Wave Life Sciences Ltd. (WVE) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
